Gosset Ownership
Private
Employees
~50
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Amphivena Therapeutics General Information
Amphivena’s lead program AMV564 has demonstrated a favorable safety profile and early signs of efficacy in Phase 1 trials for both hematologic malignancies and solid tumors. In solid tumor patients, AMV564 showed evidence of anti-tumor T cell expansion with one complete response and multiple mixed responses; importantly, no cytokine release syndrome was reported at selected doses. The drug depletes immunosuppressive MDSCs and activates effector T cells. These results support further exploration in selected indications and alternative dosing regimens.
Contact Information
Primary Industry
Biotech
Corporate Office
South San Francisco/San Francisco*, California
United States
United States
Drug Pipeline
AMV564
Phase 1Key Partnerships
Affimed AG (collaboration on bispecific TandAbs for hematologic malignancies), Merck & Co., Genentech Inc., AbCheck SRO
Amphivena Therapeutics Funding
No funding data available
To view Amphivena Therapeutics's complete valuation and funding history, request access »